| Focus V (anlotinib) / Advenchen, Sino Biopharm |
ChiCTR1800016856: A prospective, randomized, controlled clinical trial of thalidomide against small molecule VEGFR oral targeted drug grade III-IV adverse reactions |
|
|
| Recruiting | 4 | 440 | | Apatinib + thalidomide 50~150mg/d, po.QN ;Apatinib ;Anlotinib Hydrochloride + thalidomide 50~150mg/d, po.QN ;Anlotinib ;Apatinib + thalidomide 50~150mg/d, po.QN ;Apatinib ;Anlotinib Hydrochloride + thalidomide 50~150mg/d, po.QN ;Anlotinib | Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Self-raised | Patients with advanced gastric cancer, lung cancer, and osteosarcoma taking apatinib or antatinib | | | | |
| Recruiting | 4 | 1200 | | Nil | Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, CTTQ Pharmaceutical Group Co., Ltd. | Non-small cell lung cancer, soft tissue sarcoma, thyroid like cancer or other | | | | |
ChiCTR2000033298: A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with Stage IIB classic osteosarcoma of the extremity |
|
|
| Recruiting | 4 | 52 | | Anlotinib combined with Doxorubicin and cisplatin | West China Hospital of Sichuan University; West China Hospital of Sichuan University, CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD | Classic osteosarcoma | | | | |
NATARS, NCT05844813: Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma |
|
|
| Enrolling by invitation | 4 | 102 | RoW | Doxorubicin+Ifosfamide+Anlotinib(AI+A), Radical Surgery | Peking University International Hospital, Shanghai Zhongshan Hospital, The Affiliated Hospital of Qingdao University, Peking University First Hospital, Shanghai Cancer Hospital, China, First Affiliated Hospital Xi'an Jiaotong University, Beijing Friendship Hospital | Retroperitoneal Sarcoma | 11/25 | 11/27 | | |
| Active, not recruiting | 3 | 325 | Europe, US, RoW | AL3818, Catequentenib, Anlotinib, Dacarbazine, DTIC, AL3818 or placebo | Advenchen Laboratories, LLC | Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma | 12/24 | 06/25 | | |
NCT05121350: A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma |
|
|
| Recruiting | 3 | 256 | RoW | Anlotinib hydrochloride capsule, Epirubicin, Arotinib hydrochloride capsule placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Soft Tissue Sarcoma | 06/24 | 06/24 | | |
ChiCTR1800019077: The prospective, open-lable, single-arm, single-center clinical study for Anlotinib combined with AI in first-line treating patients with recurrent/metastatic soft tissue sarcoma |
|
|
| Recruiting | 2 | 20 | | Anlotinib combined with AI | affiliated Tumor Hospital, Guangxi Medical University; affiliated Tumor Hospital, Guangxi Medical University, self-financing | soft tissue sarcoma | | | | |
ChiCTR1900024928: Efficacy and safety of Anlotinib plus Epirubicin civ followed by Anlotinib sequential therapy in the first-line chemotherapy for advanced soft tissue sarcoma (STS): A single-arm phase 2 clinical trial |
|
|
| Not yet recruiting | 2 | 30 | | An+EPI→An | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Self-funding | Sarcoma | | | | |
ChiCTR1900023065: Efficacy and Safety of Anlotinib Hydrochloride (AL3818) in Postoperative Adjuvant Therapy for High-grade Soft Tissue Sarcoma — A prospective, randomized, double-blind, placebo-controlled, multicenter phase II clinical trail |
|
|
| Recruiting | 2 | 88 | | Anlotinib hydrochloride, p.o., a.c., q.d. ;Placebo, p.o., a.c., q.d. | Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, CHIA TAI TIANQING (CTTQ) Pharmaceutical Co., Ltd. | High-grade Soft Tissue Sarcoma | | | | |
NCT03946943: Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma |
|
|
| Not yet recruiting | 2 | 25 | RoW | Anlotinib, Toripalimab, Blood Draw, Phlebotomy, Tumor Specimen Collection, Core-Needle Biopsy | Di Wu | Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma | 07/22 | 07/23 | | |
ChiCTR1900025067: A prospective, open, single-center, non-randomized controlled trial for Anlotinib hydrochloride versus AI chemotherapy in the treatment of soft tissue sarcoma |
|
|
| Not yet recruiting | 2 | 61 | | doxorubicin+ifosfamide ;Anlotinib hydrochloride, p.o. | Guangxi Medical University Cancer Hospital; Guangxi Medical University Cancer Hospital, CHIA TAI TIANQING (CTTQ) Pharmaceutical Co., Ltd. | Soft Tissue Sarcoma | | | | |
NCT04765228: Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 45 | RoW | Pegylated liposomal doxorubicin, Anlotinib | Yong Chen | Stage III Adult Soft Tissue Sarcoma | 12/22 | 12/22 | | |
ChiCTR2000033377: Preoperative intensity-modulated radiotherapy (IMRT) with concurrent Anlotinib Hydrochloride for locally extremity or trunk sarcoma |
|
|
| Recruiting | 2 | 50 | | Preoperative RT with concurrent Anlotinib | Cancer Hospital of Chinese Academy of Medical Sciences; Cancer Hospital of Chinese Academy of Medical Sciences, self-raised | soft tissue sarcoma | | | | |
NCT05602415: Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 41 | RoW | Anlotinib, AL3818, Radiotherapy, Surgery | Ruijin Hospital | Soft Tissue Sarcoma, High Risk of Recurrence, Anlotinib, Radiotherapy | 01/23 | 05/24 | | |
NCT05167994: Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma |
|
|
| Recruiting | 2 | 30 | RoW | Anlotinib hydrochloride | Chinese Academy of Medical Sciences | Sarcoma,Soft Tissue, Extremity, Trunk, Anlotinib, Intensity-modulated Radiotherapy, Major Wound Complications | 04/23 | 12/23 | | |
NCT03890068: Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 48 | RoW | Anlotinib Hydrochloride, Anlotinib | Sun Yat-sen University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Soft Tissue Sarcoma | 12/23 | 05/24 | | |
ChiCTR2100055071: A single-arm phase II exploratory clinical study of sintilimab combined with anlotinib in the second-line application of unresectable or metastatic soft tissue sarcoma and osteosarcoma |
|
|
| Recruiting | 2 | 40 | | sintilimab in combination with anlotinib | Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital, Part of self-raised, part of Chia Tai Tianqing Company and Innovent Biopharmaceutical (Suzhou) Co., Ltd. | Soft tissue sarcoma and osteosarcoma | | | | |
NCT05926700: Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment |
|
|
| Recruiting | 2 | 27 | RoW | Candonilimab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Soft Tissue Sarcoma | 08/24 | 01/25 | | |
NCT04172805: Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma |
|
|
| Recruiting | 2 | 70 | RoW | anlotinib and toripalimab, Anlotinib Hydrochloride | Sun Yat-sen University | Sarcoma,Soft Tissue | 03/24 | 05/24 | | |
ChiCTR2200059629: Eribulin plus anlotinib for the treatment of refractory and advanced soft tissue sarcoma after failure of standard therapy：a prospective, open-label, single arm and single center clinical study |
|
|
| Recruiting | 2 | 30 | | Eribulin plus anlotinib | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, partly self-funded，partly provied by Eisai China Inc. | Soft tissue Sarcoma | | | | |
ChiCTR2200060410: Prospective clinical study of preoperative induction therapy with arotinib for locally advanced head and neck sarcoma |
|
|
| Not yet recruiting | 2 | 31 | | 2 cycles of neoadjuvant therapy with anlotinib | Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, self-funded | head and neck sarcoma | | | | |
NCT05481645: Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. |
|
|
| Recruiting | 2 | 79 | RoW | TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Paclitaxel Injection, Doxorubicin Hydrochloride Injection, Gemcitabine Hydrochloride Injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer, Sarcoma of Uterus | 06/24 | 12/24 | | |
ChiCTR2100053490: A phase 2 study of Surufatinib in patients after first line standard chemotherapy or Anlotinib treatment failure of soft tissue sarcoma |
|
|
| Recruiting | 2 | 64 | | Surufatinib+Gemcitabine ;Surufatinib | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Part of self-raised, part of Hutchison Whampoa Pharmaceuticals (Shanghai) Co., Ltd. | Soft Tissue Sarcoma | | | | |
ChiCTR2100054711: Anlotinib combined with AI followed by anlotinib sequential therapy for the first-line treatment of recurrent/metastatic soft tissue sarcoma: a prospective, open-label, single arm, single-center clinical study |
|
|
| Recruiting | 2 | 50 | | Anlotinib combined with AI followed by Anlotinib sequential therapy | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, partly self-funded, partly provied by CTTQ | soft tissue Sarcoma | | | | |
NCT05193188: A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma |
|
|
| Recruiting | 2 | 70 | RoW | Anlotinib hydrochloride, FuKeWei, PD-1 inhibitor | Second Affiliated Hospital, School of Medicine, Zhejiang University | Chondrosarcoma | 03/25 | 03/26 | | |
TORAN, ChiCTR2100054901: A phase II trial of anlotinib and toripalimab as maintenance therapy in patients with advanced soft tissue sarcoma after anthracycline-based chemotherapy |
|
|
| Recruiting | 2 | 50 | China | Anlotinib + Toripalimab | West China Hospital, Sichuan University ; West China Hospital, Sichuan University, West China Hospital, Sichuan University; Shanghai Junshi Biosciences Co., Ltd.; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Soft tissue sarcoma | | | | |
ChiCTR2300072293: An exploratory study on the first-line treatment of advanced unresectable soft tissue sarcoma with zimberelimab administered in combination with anlotinib and eribulin |
|
|
| Recruiting | 2 | 30 | | zimberelimab administered in combination with anlotinib and eribulin | Sanhuan Cancer Hospital, Chaoyang District, Beijing; Sanhuan Cancer Hospital, selt-funded | soft tissue sarcoma | | | | |
ChiCTR2300067650: Safety and efficacy of eribulin combined with anlotinib followed by anlotinib maintenance in advanced soft tissue sarcoma patients with intolerance or failure of doxorubicin-based chemotherapy: a prospective single-arm phase II study |
|
|
| Not yet recruiting | 2 | 30 | | Treatment with eribulin and anlotinib | West China Hospital, Sichuan University; West China Hospital, Sichuan University, No | Soft-Tissue Sarcoma | | | | |
TEASTS, ChiCTR2300071221: Efficacy of Tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult soft tissue sarcoma |
|
|
| Recruiting | 2 | 26 | China | Tislelizumab + iribrin + arotinib | Zhongshan Hospital, Fudan University ; Zhongshan Hospital, Fudan University, Zhongguancun Foundation | soft tissue sarcoma (STS) | | | | |
NCT04165330: Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 56 | US | AL3818, Anlotinib hydrochloride, Nivolumab Injection, Opdivo | Sarcoma Oncology Research Center, LLC, Advenchen Laboratories, LLC | Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer | 12/24 | 03/25 | | |
NCT05301764: A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma |
|
|
| Recruiting | 1/2 | 65 | RoW | LVGN6051 and Anlotinib | Lyvgen Biopharma Holdings Limited | Soft Tissue Sarcoma | 03/25 | 10/25 | | |
ChiCTR2100048014: A multi-center, single-arm clinical trial of penpulimab (AK105) combined with anlotinib hydrochloride and epirubicin in the first-line treatment of soft tissue sarcoma |
|
|
| Not yet recruiting | 1/2 | 78 | | Penpulimab + Anlotinib Hydrochloride + Epirubicin（dose escalation） ;Penpulimab + Anlotinib Hydrochloride + Epirubicin | Zhongshan Hospital of Fudan University; Zhongshan Hospital of Fudan University, Partly self-funded，partly provied by CTTQ. | Sarcoma | | | | |
| Ongoing | 1b | 30 | China | benmelstobart (APL-502) - Apollomics, Focus V (anlotinib) - Advenchen, Sino Biopharm | Nanjing Shunxin Pharmaceutical Co., Ltd./ Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Advanced soft tissue sarcoma | | | | |
NCT04659733: Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children |
|
|
| Not yet recruiting | 1 | 36 | NA | Anlotinib hydrochloride | Yizhuo Zhang | Sarcoma | 12/22 | 12/22 | | |
| Recruiting | 1 | 43 | RoW | 1200mg of TQB2928 injection+Anlotinib, 1800mg of TQB2928 injection+Anlotinib | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Osteosarcoma, Other Solid Tumors | 10/25 | 02/26 | | |
ChiCTR2300068691: Pharmacokinetic study of anlotinib hydrochloride capsules in the treatment of relapsed or refractory pediatric sarcoma |
|
|
| Not yet recruiting | 1 | 36 | | Anlotinib | The Children’s Hospital, Zhejiang University School of Medicine; The Children’s Hospital, Zhejiang University School of Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Sarcoma | | | | |
NCT05612191: Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial) |
|
|
| Available | N/A | | NA | AL3818, Catequentinib (AL3818, Anlotinib) Hydrochloride | Advenchen Laboratories, LLC | Sarcoma,Soft Tissue, Gynecologic Cancer | | | | |
ChiCTR2100048715: Clinical trial of Chidamide in combination with Anlotinib for refractory and advanced soft tissue sarcoma after failure of standard therapy |
|
|
| Not yet recruiting | N/A | 56 | | Treatment was performed according to the combination regimen of cidabentamine and amlotinib | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Shanghai Sixth People's Hospital | soft tissue sarcoma | | | | |
ChiCTR2000036618: Precision therapy strategy for osteosarcoma based on molecular typing: a prospective, single-center, one-brachial umbrella phase II exploratory clinical study |
|
|
| Not yet recruiting | N/A | 18 | | Everolimus 5mg qd + Anlotinib 8mg-12mg day 1-21，28-day cycle ;Camrelizumab 3mg/kg + Ipilimumab 1 mg/kg, 21-days cycle ;Palbociclib 125mg day 1-21 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Olaparib 300mg bid day 1-14 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Metformin 2000mg qd + gemcitabine 675mg/m2 day 1,8, docetaxol 900mg/m2 day 8， 21-days cycle | Shanghai General Hospital; Shanghai General Hospital, Project special fund | osteosarcoma | | | | |
NCT05490667: Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor |
|
|
| Recruiting | N/A | 30 | RoW | Anlotinib, chemotherapy | Henan Cancer Hospital | Desmoid | 07/24 | 07/24 | | |
NCT05747521: Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma |
|
|
| Recruiting | N/A | 85 | RoW | Anrotinib hydrochloride combined with adriamycin | Henan Cancer Hospital | Soft Tissue Sarcoma | 09/24 | 09/24 | | |
